Sebum production inhibitor

The cosmetic method using photoresponsive sebum inhibitors like carnitine and camellia flower extract enhances sebum suppression by light exposure, addressing excessive sebum-related issues and diseases.

JP2024164571APending Publication Date: 2024-11-27SHISEIDO CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2023080153
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-05-15
Publication Date
2024-11-27

AI Technical Summary

Technical Problem

Excessive sebum production leads to cosmetic issues such as stickiness, shine, keratin plugs, enlarged pores, acne, and skin diseases like seborrheic eczema and rosacea, and existing sebum inhibitors are inadequate in efficacy.

Method used

A cosmetic method using photoresponsive sebum production inhibitors like carnitine, camellia flower extract, lemon extract, fisetin, and honokiol, applied to the skin and exposed to light, enhances the sebum production inhibitory effect.

Benefits of technology

The method effectively reduces sebum production, addressing cosmetic issues and skin diseases by increasing the inhibitory effect when exposed to light.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024164571000001_ABST
    Figure 2024164571000001_ABST
Patent Text Reader

Abstract

To obtain a sebum production inhibitor, and to enhance the sebum production inhibition effect of the obtained sebum production inhibitor.SOLUTION: The present inventors have completed an experimental system for screening sebum production inhibitors, and screened candidate cosmetic ingredients, discovering that carnitine or a salt thereof, lemon extract, camellia flower extract, fisetin, honokiol, and diosmin have a sebum production inhibitory effect, thereby providing a sebum production inhibitor. The present inventors have discovered that the sebum production inhibitory effect is enhanced when the sebum production inhibitor is exposed to visible light, and provide a cosmetic method for enhancing the sebum production inhibitory effect, which comprises applying to the skin a skin topical composition containing a photoresponsive sebum production inhibitor, and placing the skin after application in the presence of light.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure relates to the technical field of sebum production inhibition. More specifically, the present disclosure relates to a sebum production inhibitor, and further to a cosmetic method for enhancing the sebum production inhibitory effect, comprising applying a skin topical composition containing the sebum production inhibitor to skin and placing the applied skin in the presence of light. [Background technology]

[0002] Sebum is a component mainly composed of fat secreted from sebaceous glands. The components of the skin are mainly composed of lipid components such as triglycerides, wax esters, squalene, and cholesterol, and some of them are decomposed by skin resident bacteria to become more complex. The action of skin resident bacteria decomposes the secreted fat into fatty acids, thereby keeping the skin surface weakly acidic. In addition, the skin surface is covered with sebum, which suppresses water evaporation from the skin surface, and thus sebum contributes to the moisture retention of the skin. Thus, sebum plays an important role in protecting the skin. On the other hand, excessive production of sebum leads to skin properties such as stickiness, shininess, keratin plugs, and enlarged pores. In addition, the production of sebum can cause beauty problems such as makeup breakdown, odor, and greasy hair. Furthermore, pores are clogged with sebum, which can cause acne and pimples, as well as other skin diseases such as seborrheic eczema, senile sebaceous hyperplasia, sebaceous nevus, rosacea, and alopecia. In addition, it is known that when the lipids in the produced sebum are oxidized to become lipid peroxides, they damage skin elastic fibers such as collagen and elastin, leading to skin aging and pigmentation. Therefore, while moderate sebum production is necessary to maintain healthy skin, excessive sebum production is undesirable from a cosmetic standpoint, and suppressing excessive sebum production is an important issue in terms of cosmetics and the treatment of skin diseases.

[0003] Sebum is synthesized in the sebaceous glands located in the pores and is produced on the skin surface through the pores. It has been reported that plant extracts such as bamboo extract, quince extract, and celosia plants, as well as carotenoids and their derivatives, have an inhibitory effect on sebum production (Patent Document 1: JP 2021-181494 A, Patent Document 2: JP 2013-32331 A, Patent Document 3: JP 2011-140460 A, and Patent Document 4: JP 2013-028572 A). [Prior art documents] [Patent documents]

[0004] [Patent Document 1] JP 2021-181494 A [Patent Document 2] JP 2013-32331 A [Patent Document 3] JP 2011-140460 A [Patent Document 4] JP 2013-028572 A Summary of the Invention [Problem to be solved by the invention]

[0005] An object of the present invention is to obtain a sebum production inhibitor, and an object of the present invention is to enhance the sebum production inhibitory effect of the obtained sebum production inhibitor. [Means for solving the problem]

[0006] The present inventors have completed an experimental system for screening sebum production inhibitors, and have screened candidate cosmetic ingredients, finding that carnitine or its salts, lemon extract, camellia flower extract, fisetin, honokiol, and diosmin have sebum production inhibitory effects.Furthermore, the inventors have found that the sebum production inhibitory effect of a component selected from the group consisting of carnitine or its salts, camellia flower extract, lemon extract, mangosteen extract, diosmin, raspberry extract, honokiol, camellia leaf extract, and fisetin is enhanced by applying the component and then placing it under visible light, which led to the present invention.

[0007] Therefore, the present application provides the following invention. [1] A cosmetic method for enhancing the sebum production inhibitory effect, comprising applying to the skin a skin topical composition containing at least one light-responsive sebum production inhibitor selected from the group consisting of carnitine or a salt thereof, camellia flower extract, lemon extract, mangosteen extract, diosmin, raspberry extract, honokiol, camellia leaf extract, and fisetin, and placing the skin after application in the presence of light. [2] The cosmetic method according to item 1, wherein the sebum production inhibitory effect of the sebum production inhibitor is enhanced in the presence of light. [3] The beauty method described in item 1 or 2 for preventing stickiness, greasiness, and makeup from coming off. [4] A sebum production inhibitor comprising at least one ingredient selected from the group consisting of carnitine or a salt thereof, lemon extract, camellia flower extract, fisetin, honokiol, and diosmin. [5] The sebum production inhibitor according to item 4, wherein the sebum production inhibitory effect is enhanced in the presence of light. [6] The sebum production inhibitor according to item 4 or 5, contained in a light-shielding container. [7] A cosmetic composition for external application to the skin, comprising the sebum production inhibitor according to any one of items 4 to 6, for preventing stickiness, greasiness, or makeup from coming off. [8] The topical skin composition described in Item 7, further comprising a wavelength conversion substance that converts ultraviolet light into visible light. [9] A composition for external application to the skin for preventing, treating, or alleviating a disease caused by excessive sebum production, comprising the sebum production inhibitor according to any one of items 4 to 6.

[10] The topical skin composition described in Item 9, further comprising a wavelength conversion substance that converts ultraviolet light into visible light.

[11] In the manufacture of a skin topical composition for inhibiting sebum production, use of at least one component selected from the group consisting of carnitine or a salt thereof, camellia flower extract, lemon extract, mangosteen extract, diosmin, raspberry extract, honokiol, camellia leaf extract, and fisetin to enhance the inhibitory effect of sebum production in the presence of light.

[12] A device for enhancing the sebum production inhibitory effect of a photoresponsive sebum production inhibitor, comprising an irradiation unit that irradiates light having a wavelength of 370 to 780 nm onto skin to which the photoresponsive sebum production inhibitor has been applied.

[13] A beauty kit for enhancing a sebum production inhibitory effect, comprising: a composition for external use on the skin, comprising at least one photoresponsive sebum production inhibitor selected from the group consisting of carnitine or a salt thereof, camellia flower extract, lemon extract, mangosteen extract, diosmin, raspberry extract, honokiol, camellia leaf extract, and fisetin; The kit further comprises an irradiation unit that irradiates light having a wavelength of 370 to 780 nm onto the skin to which the photoresponsive sebum production inhibitor has been applied, and a device for enhancing the sebum production inhibitory effect of the photoresponsive sebum production inhibitor. Effect of the Invention

[0008] The sebum production inhibitor of the present invention inhibits sebum production. Furthermore, by placing the skin after application of the photoresponsive sebum production inhibitor in the presence of light, the sebum production effect is enhanced. [Brief description of the drawings]

[0009] [Figure 1] Figure 1 shows the results of screening for components that suppress sebum production in sebaceous gland cells. The amount of sebum produced was measured without and with light irradiation, and the percentage of the amount of sebum produced relative to the control is shown. [Diagram 2] FIG. 2 shows the ratio (%) of the amount of sebum produced under light irradiation to the amount of sebum produced without light irradiation. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0010] The present invention relates to a sebum production inhibitor. It also relates to a cosmetic method for enhancing the sebum production inhibitory effect, which comprises applying a skin topical composition containing a sebum production inhibitor to the skin and placing the skin in the presence of light after application. A sebum production inhibitor whose sebum production inhibitory effect is enhanced in the presence of light is called a light-responsive sebum production inhibitor. In addition, among the light-responsive sebum production inhibitors, a sebum production inhibitor that does not have a sebum production inhibitory effect in the absence of light and has a sebum production inhibitory effect only in the presence of light can be called an exclusively light-responsive sebum production inhibitor.

[0011] [Sebum production inhibitor] In the present invention, at least one component selected from the group consisting of carnitine or its salt, lemon extract, camellia flower extract, fisetin, honokiol, and diosmin is used as the sebum production inhibitor. These sebum production inhibitors have a sebum production inhibitory effect even in the absence of light, but the sebum production inhibitory effect is enhanced under light irradiation. Therefore, these sebum production inhibitors can be called facultative light-responsive sebum production inhibitors.

[0012] In the present invention, at least one component selected from the group consisting of raspberry extract, mangosteen extract, and camellia leaf extract is used as the photoresponsive sebum production inhibitor. These photoresponsive sebum production inhibitors do not have a sebum production inhibitory effect in the absence of light, but exhibit a sebum production inhibitory effect when exposed to light.

[0013] The facultative photoresponsive sebum production inhibitor and the partial photoresponsive sebum production inhibitor can be collectively referred to as a photoresponsive sebum production inhibitor. Therefore, the photoresponsive sebum production inhibitor uses at least one component selected from the group consisting of carnitine or a salt thereof, camellia flower extract, lemon extract, mangosteen extract, diosmin, raspberry extract, honokiol, camellia leaf extract, and fisetin.

[0014] The present invention may further relate to a skin topical composition comprising the sebum production inhibitor or photoresponsive sebum production inhibitor of the present invention. The skin topical composition may be a cosmetic composition or a pharmaceutical composition. The cosmetic composition of the present invention is a cosmetic skin topical composition for suppressing any action caused by the inhibition of sebum production, such as stickiness of the skin, shininess, keratin plugs, enlarged pores, makeup breakdown, odor, greasy hair, acne, and pimples. The pharmaceutical composition of the present invention relates to a pharmaceutical composition for treating, preventing, or alleviating any disease that can be treated, prevented, or alleviated by the inhibition of sebum production, such as at least one skin disease selected from acne, seborrheic eczema, senile sebaceous hyperplasia, sebaceous nevus, rosacea, and alopecia. When the skin topical composition of the present invention comprises a photoresponsive sebum production inhibitor, the skin topical composition is characterized by a method of use in which the skin after application is placed in the presence of light. Such a method of use may be clearly stated on the product package, advertisement, instruction manual, etc. The skin topical composition of the present invention may further contain a wavelength conversion substance. As a result, even when the topical skin preparation applied to the skin is exposed to ultraviolet rays outdoors, the ultraviolet rays are converted into visible light and act on the photoresponsive sebum production inhibitor, thereby exerting its sebum production inhibitory effect.

[0015] In the present invention, the wavelength converting substance refers to a substance that absorbs incident light of a specific wavelength and emits outgoing light of a longer wavelength than the incident light. The incident light absorbed by the wavelength converting substance of the present invention is preferably ultraviolet light. The outgoing light emitted by the wavelength converting substance has a longer wavelength than ultraviolet light, and preferably has a peak wavelength of 450 nm to 700 nm, more preferably 500 nm to 700 nm. In an embodiment, the wavelength converting substance exhibits a main wavelength of 450 nm to 700 nm, more preferably 500 nm to 700 nm, of light emitted when excited with excitation light of 200 nm to 400 nm.

[0016] Examples of wavelength converting substances include the following components: phycobiliproteins such as allophycocyanin, C-phycocyanin, R-phycocyanin, phycoerythrocyanin, B-phycoerythrin, b-phycoerythrin, C-phycoerythrin, and R-phycoerythrin; natural or synthetic components such as vitamin A, vitamin K, vitamin B1, vitamin B6, vitamin B12, folic acid, niacin, gardenia, safflower, turmeric, cochineal, perilla, red cabbage, flavonoids, carotenoids such as β-carotene, lycopene, quinoids, porphyrins, anthocyanins, and polyphenols; Red No. 401, Red No. 227, Red No. 504, Red No. 218, Orange No. 205 P, Yellow No. 4, Yellow No. 5, Green No. 201, Pyranine Concentrate, Blue No. 1, Dyes such as 2,4-diaminophenoxyethanol hydrochloride, Alizurin Purple SS, Purple No. 401, Black No. 401, Herringbone Pink, Yellow No. 401, Benzidine Yellow G, Blue No. 404, Red No. 104, and meta-aminophenol; phosphors doped with inorganic compounds to give them fluorescence, for example, a blue phosphor containing amorphous silica particles, cerium, phosphorus, and / or magnesium as described in Japanese Patent No. 6424656 and a red phosphor containing a compound obtained by activating a mixed crystal of an alkaline earth metal sulfide and a gallium compound with europium as described in Japanese Patent No. 6361416, a zinc oxide phosphor as described in International Publication No. 2018 / 004006, a zinc oxide phosphor as described in Japanese Patent Publication No. 2018-131422, an inorganic phosphor as described in Japanese Patent Publication No. 5-117127, and the like. In one embodiment, the inorganic phosphor is ZnO:Zn, Zn 1+z , ZnO 1-xand phosphors doped with sulfur-containing compounds, such as zinc sulfide, zinc sulfate, and / or other sulfides and / or sulfates, as described in WO 2018 / 004006, such as MgTiO 3 , Mg 2 TiO 4 Magnesium titanate phosphors such as magnesium titanate doped with manganese, and Ca(H 2 PO 4 ) 2 , CaHPO 4 , Ca 3 (PO 4 ) 2 The phosphor is one or more phosphors selected from calcium phosphate phosphors obtained by doping calcium phosphate with cerium, such as those mentioned above.

[0017] The wavelength conversion substance may be obtained by a method such as extraction from natural products such as animals, plants, and algae, or by an artificial method such as chemical synthesis. For example, phycobiliprotein may be prepared by extracting algae such as blue-green algae such as Spirulina platensis and red algae such as Porphyridium purpureum by a method such as that described in Japanese Patent No. 4048420, Japanese Patent No. 4677250, Japanese Patent No. 3303942, etc. Zinc oxide phosphor may be produced by a method such as that described in International Publication No. 2018 / 004006, Japanese Patent Publication No. 2018-131422, and Japanese Patent Publication No. 5-117127. Magnesium titanate phosphor may be produced by a method described in Japanese Patent Publication No. 2017-88719. Calcium phosphate phosphor may be produced by a method described in International Publication No. 2018 / 117117. Among these, from the viewpoint of emitting visible light of a wavelength beneficial to the skin at a more appropriate intensity, a substance selected from the group consisting of zinc oxide phosphor, magnesium titanate phosphor, and C-phycocyanin can be used as the wavelength conversion substance.

[0018] The present invention also relates to the use of at least one component selected from the group consisting of carnitine or a salt thereof, camellia flower extract, lemon extract, mangosteen extract, diosmin, raspberry extract, honokiol, camellia leaf extract, and fisetin in the manufacture of an external skin composition for inhibiting sebum production, for enhancing the inhibitory effect on sebum production in the presence of light.

[0019] [Beauty method] The present invention also relates to a cosmetic method for enhancing the sebum production inhibitory effect, which comprises applying a skin topical composition containing a photoresponsive sebum production inhibitor to the skin and placing the skin in the presence of light after application. The skin to which the skin topical composition containing a photoresponsive sebum production inhibitor has been applied is placed in the presence of light, thereby enhancing the sebum production inhibitory effect. The light may be only visible light, may be white light containing ultraviolet light, or may be natural light, and light that enhances the sebum production inhibitory effect of the photoresponsive sebum production inhibitor can be appropriately selected. Being placed in the presence of light may be exposure to electric lights or sunlight in daily life, or may be irradiation of light using a device equipped with an irradiation unit. The cosmetic method of the present invention may include irradiating the skin topical composition containing a photoresponsive sebum production inhibitor with light of a specific wavelength after application, thereby enhancing the sebum production inhibitory effect of the applied skin topical composition. From the viewpoint of including a step of irradiating light, it is preferable that ultraviolet rays harmful to the skin are removed, and it is preferable to irradiate only visible light. More preferably, visible light having a wavelength capable of enhancing the sebum production inhibitory effect is irradiated depending on the component. The cosmetic method of the present invention can be performed, for example, in a beauty salon, by a cosmetic practitioner other than a doctor, using an irradiator capable of irradiating visible light of a specific wavelength.

[0020] In one embodiment, the skin external composition according to the present invention is applied to the skin, and light to be irradiated is selected according to the type of photoresponsive sebum production inhibitor contained in the skin external composition, and can be irradiated using a light irradiator. Examples of the light to be irradiated include visible light and white light. Visible light is light that does not contain ultraviolet light or infrared light, while white light refers to light that contains ultraviolet light and / or infrared light. From the viewpoint of avoiding ultraviolet light, it is preferable to irradiate visible light. Light that enhances the sebum production inhibitory effect can be appropriately selected according to the type of photoresponsive sebum production inhibitor. Among visible light, light having a specific wavelength selected from red, orange, yellow, green, blue, indigo, and purple can also be selected. Usually, visible light can be irradiated by attaching an ultraviolet filter and / or an IR filter that cuts ultraviolet light to a light source such as a solar simulator, or can be irradiated using a light source that suppresses the generation of ultraviolet light in advance. White light refers to light that includes ultraviolet light with a wavelength of 400 nm or less, visible light with a wavelength of 400 to 760 nm, and infrared light with a wavelength of 800 nm or more, each of which does not have a significant bias in the energy balance. The white light may be natural light or may be emitted from a light source that simulates natural light, such as a solar simulator, without a filter.

[0021] The irradiation intensity and irradiation time of visible light can be appropriately selected depending on the light irradiator. They can be appropriately set based on the irradiation intensity and irradiation time that are effective in cell experiments according to the sebum production measurement method. As an example, the intensity of visible light is 1 to 100 mW / cm 2 In order to exert a sufficient sebum production inhibitory effect, the visible light intensity is preferably 10 mW / cm 2 More than 20mW / cm is preferable. 2 More preferably, the visible light intensity is 50 mW / cm or less because too high an intensity may cause toxicity to cells. 2 Less than 30mW / cm is preferable. 2 The following is even more preferable. From the viewpoint of exerting a sufficient sebum production inhibitory effect, it is preferable to irradiate for 10 minutes or more, more preferably for 30 minutes or more.

[0022] The sebum production inhibitor, beauty method, and skin topical composition of the present invention enhance the sebum production inhibitory effect in the skin, thereby treating or preventing cosmetic troubles such as sticky skin, shininess, keratin plugs, enlarged pores, makeup loss, odor, greasy hair, acne, and pimples, as well as skin diseases such as seborrheic eczema, senile sebaceous hyperplasia, sebaceous nevus, rosacea, and alopecia. Therefore, the subject to which the beauty method and skin topical composition of the present invention are applied is preferably a subject suffering from sebum production. Subjects suffering from sebum production include subjects suffering from at least one cosmetic trouble selected from sticky skin, shininess, keratin plugs, enlarged pores, makeup loss, odor, greasy hair, acne, and pimples, or at least one skin disease selected from seborrheic eczema, senile sebaceous hyperplasia, sebaceous nevus, rosacea, and alopecia.

[0023] [Measurement of sebum production] In the present invention, the amount of sebum production may be measured by swabbing the amount of sebum produced in vivo or by appearance such as shine. In yet another embodiment, the amount of sebum production can be measured by culturing sebaceous gland cells or organ culture of sebaceous glands in vitro. By applying a specific ingredient and / or irradiating with light, the change in the amount of sebum production can be measured to determine the sebum production inhibitory effect.

[0024] In yet another embodiment, the present invention may relate to a method for screening a sebum production inhibitor. The sebum production inhibitor can be screened by using the amount of oil droplets in cultured sebaceous gland cells as an index. More specifically, the following: Culturing sebaceous gland cells in a medium containing a candidate component; Measuring the amount of oil droplets in sebaceous gland cells during or after culturing in a medium containing a candidate drug; and A step of comparing the measured amount of oil droplets with a control to determine the sebum production inhibitory effect of the candidate drug. Includes. If the amount of oil droplets is reduced, the candidate component can be screened as a sebum production inhibitor. The amount of oil droplets can be measured by staining the oil droplets with a stain such as oil red. As a control, the amount of sebum production in a vehicle control (a control to which only the candidate component is not added) can be used. In yet another embodiment, a step of irradiating light, particularly visible light, to a medium containing the candidate component during the culturing step may be included. The light irradiation conditions can be those described herein. In this case, the sebum production inhibitory effect can be determined by comparing the amount of sebum production when irradiated with light to the amount of sebum production in a control not irradiated with light.

[0025] Candidate components used in the screening method of the present invention can be any library of cosmetic materials, food materials, pharmaceutical materials, etc. Such libraries may be compound libraries, extract libraries, etc. The compounds and extracts contained in each library may be commercially available compounds and extracts, or may be synthesized compounds and prepared extracts. In the screening method of the present invention, components determined to have a sebum production inhibitory effect include levocarnitine chloride, lemon extract, camellia flower extract, diosomine, fisetin, and honokiol. In addition, components whose sebum production inhibitory effect is enhanced under light irradiation include levocarnitine chloride, lemon extract, camellia flower extract, diosomine, fisetin, honokiol, raspberry extract, mangosteen extract, and camellia leaf extract.

[0026] Camellia flower extract is an extract obtained by solvent extraction from the flowers of Camellia japonica, which is native to Japan. It can be prepared by extraction using water, alcohol, or a mixture thereof as a solvent. As the alcohol, ethanol, glycerol, butylene glycol, and propylene glycol can be used. More preferably, it can be extracted using a mixture of water and ethanol or water and 1,3-butylene glycol in any ratio, for example, a mixture of 10:90 to 90:10, preferably a mixture of 30:70 to 70:30, and more preferably a mixture of 50:50. Camellia flower extract is known to have various beauty effects, including antioxidant effects. Camellia flower extract is blended in cosmetics at a concentration of 0.000001% to 1.0%, more preferably 0.001% to 0.1%.

[0027] Camellia leaf extract is an extract obtained by solvent extraction from the leaves of Camellia japonica, which is native to Japan. It can be prepared by extraction using water, alcohol, or a mixture thereof as the solvent. As the alcohol, ethanol, glycerol, butylene glycol, and propylene glycol can be used. More preferably, it can be extracted using a mixture of water and ethanol or water and 1,3-butylene glycol in any ratio, for example, a mixture of 10:90 to 90:10, preferably a mixture of 30:70 to 70:30, and more preferably a mixture of 50:50. Camellia leaf extract has antioxidant activity, elastase inhibitory activity, estrogen-like activity, and the like, and is known to have beauty effects such as anti-aging. Camellia leaf extract is blended in cosmetics, quasi-drugs, or pharmaceuticals at a concentration of 0.000001% to 1.0%, more preferably 0.001% to 0.1%.

[0028] Lemon extract is an extract obtained by solvent extraction from the fruit of lemon (Citrus limon), which is widely cultivated as a cultivated species. As an example, lemon extract can be prepared by extraction using water, alcohol, or a mixed solvent thereof as a solvent. As the alcohol, ethanol, glycerol, butylene glycol, and propylene glycol can be used. More preferably, it can be extracted using a mixed solution of water and ethanol or water and 1,3-butylene glycol in any ratio, for example, a mixed solution of 10:90 to 90:10, preferably a mixed solution of 30:70 to 70:30, and more preferably a mixed solution of 50:50. Lemon extract contains organic acids such as citric acid and malic acid, and terpenoids such as citral, and is known to have beauty effects such as a tightening action. Lemon extract is blended in cosmetics, quasi-drugs, or pharmaceuticals at a concentration of 0.000001% to 1.0%, more preferably 0.001% to 0.1%.

[0029] The raspberry extract is an extract obtained by solvent extraction from the fruit of raspberry (Rubus Idaeus), which grows wild widely from the cold zone to the temperate zone of the Northern Hemisphere. The raspberry extract can be prepared by extraction using water, alcohol, or a mixture thereof as a solvent. As the alcohol, ethanol, glycerol, butylene glycol, and propylene glycol can be used. More preferably, the extract can be extracted using a mixture of water and ethanol or water and 1,3-butylene glycol in any ratio, for example, a mixture of 10:90 to 90:10, preferably a mixture of 30:70 to 70:30, and more preferably a mixture of 50:50. The raspberry extract contains flavonoids such as anthocyanins and vitamins such as ascorbic acid, and is known to have anti-allergic effects, melanin production inhibitory effects, and cosmetic effects such as age spot inhibition and anti-aging inhibition. Rubus idaeus extract is blended in cosmetics, quasi-drugs or pharmaceuticals at a concentration of 0.000001% to 1.0%, and more preferably 0.001% to 0.1%.

[0030] Mangosteen extract is an extract obtained by solvent extraction from the fruit of mangosteen (Garcinia mangostana L.) native to Southeast Asia. For example, mangosteen extract can be prepared by extraction using water, alcohol, or a mixture thereof as a solvent. As the alcohol, ethanol, glycerol, butylene glycol, and propylene glycol can be used. More preferably, it can be extracted using a mixture of water and ethanol or water and 1,3-butylene glycol in any ratio, for example, a mixture of 10:90 to 90:10, preferably a mixture of 30:70 to 70:30, and more preferably a mixture of 50:50. It is known that mangosteen extract contains rhodanthenone B, which exerts an anti-glycation effect and is known to have cosmetic effects such as anti-aging inhibition. Mangosteen extract is blended in cosmetics, quasi-drugs, or pharmaceuticals at a concentration of 0.000001% to 1.0%, more preferably 0.001% to 0.1%.

[0031] Carnitine has the following formula: [ka] Carnitine or its salt is a compound represented by the formula: Carnitine or its salt is a component contained in red meat, and is known to be involved in lipid metabolism. As carnitine, L-carnitine is particularly preferable. Carnitine is blended in cosmetics, quasi-drugs, or pharmaceuticals at a concentration of 0.01% to 5%, more preferably 0.1% to 1%.

[0032] Diosmin has the following formula: [ka] Diosmin is a flavonoid glycoside contained in citrus fruits. Diosmin is known to have a vascular protective effect. Diosmin is blended in cosmetics, quasi-drugs, or pharmaceuticals at a concentration of 0.0001% to 1.0%, and more preferably 0.001% to 0.1%.

[0033] Honokiol has the following formula: [ka] Honokiol is a type of polyphenol contained in the bark of the magnolia tree, and has an antioxidant effect. Honokiol is used as a traditional Chinese medicine, and has been reported to have physiological effects such as analgesic, anti-inflammatory, and anti-cancer effects. Honokiol is blended in cosmetics, quasi-drugs, or pharmaceuticals at a concentration of 0.0001% to 1.0%, and more preferably 0.001% to 0.1%.

[0034] Fisetin has the formula: [ka] Fisetin is a type of flavonoid found in strawberries, cognac, etc., and has been reported to have antioxidant properties, as well as anti-inflammatory, anti-cancer, and anti-aging properties. It is blended in cosmetics, quasi-drugs, or pharmaceuticals at a concentration of 0.0001% to 1.0%, and more preferably 0.001% to 0.1%.

[0035] The extract described in this specification can be obtained by a conventional method, for example, by immersing or refluxing the plant with an extraction solvent at room temperature or at high temperature, followed by filtration and concentration. As the extraction solvent, any solvent that is usually used for extraction can be used, for example, aqueous solvents such as water, physiological saline, phosphate buffer, borate buffer, or organic solvents such as alcohols such as ethanol, propylene glycol, 1,3-butylene glycol, glycerin, hydrous alcohols, chloroform, dichloroethane, carbon tetrachloride, acetone, ethyl acetate, hexane, etc., can be used alone or in combination. Preferably, a mixed solvent of water and alcohol, such as 1,3-butylene glycol, is used as the solvent. The extract obtained by extraction with the above solvent can be used as it is, or the extract can be concentrated by, for example, freeze-drying, and if necessary, it can be used after removing impurities using an adsorption method, for example, an ion exchange resin, or after adsorption on a column of porous polymer (e.g., Amberlite XAD-2), eluted with a desired solvent, and further concentrated.

[0036] The skin external composition of the present invention may be any skin external composition as long as it contains the photoresponsive sebum production inhibitor specified in the present invention. Such a skin external composition may be a medicine, a quasi-drug, a cosmetic, etc. The formulation, application method, number of administrations, etc. of the skin external composition used in the cosmetic method of the present invention can be arbitrarily determined. For example, it may be in the form of a lotion, a spray, an oil, a cream, a milky lotion, a gel, a sunscreen, a suntan agent, etc. Before the light irradiation in the cosmetic method of the present invention, the skin external composition may be applied once or a plurality of times, and light may be irradiated immediately thereafter or for a certain period of time, for example, 10 minutes to several hours. Instead of light irradiation, light may be irradiated by being active outdoors or indoors with the light turned on. The skin external composition according to the present invention may be characterized by being stored in a light-shielding container. The photoresponsive sebum production inhibitor contained in the skin external composition of the present invention has an increased sebum production inhibitory effect by light irradiation, but the stability of the photoresponsive sebum production inhibitor may be lost by light irradiation. Therefore, by storing the photoresponsive sebum production inhibitor in a light-shielding container, it is possible to stably maintain the photoresponsive sebum production inhibitor until immediately before application.

[0037] In addition, the skin topical composition of the present invention may contain additives such as excipients, preservatives, thickeners, binders, disintegrants, dispersants, stabilizers, gelling agents, antioxidants, surfactants, preservatives, oils, powders, water, alcohols, thickeners, chelating agents, silicones, antioxidants, moisturizing agents, fragrances, various medicinal ingredients, preservatives, pH adjusters, neutralizers, etc., which may be selected arbitrarily and used in combination. Furthermore, in order to enhance the effects of the present invention, other cell activators, etc. may be used in combination.

[0038] [Device] The light irradiator may be a handy type or a whole body type for irradiating only the skin to which the external composition for skin is applied.The external composition for skin may be applied to the skin of the whole body, but may be applied to any part of the skin such as the face, head, limbs, or body from the viewpoint of exerting the sebum production suppressing effect.

[0039] [Beauty Kit] In a further aspect of the present invention, the present invention may relate to a beauty kit comprising a skin external composition containing a sebum production inhibitor and an irradiator for irradiating visible light of 1000 to 100000 Lux with a wavelength in the visible light range, particularly a wavelength of 450 to 700 nm, 450 to 600 nm, or 500 to 550 nm. Such a beauty kit may be used by a purchaser or a beauty practitioner. The irradiator for irradiating visible light can be irradiated by using an irradiator well known in the art. From the viewpoint of irradiating visible light in a predetermined peak range, it is preferable to adjust the irradiated wavelength using an LED and, if necessary, a filter.

[0040] All documents mentioned in this specification are incorporated herein by reference in their entirety. The following examples of the present invention are for illustrative purposes only and do not limit the technical scope of the present invention. The technical scope of the present invention is limited only by the claims. The present invention can be modified, for example, by adding, deleting, and replacing the constituent elements of the present invention, without departing from the spirit of the present invention. EXAMPLES

[0041] Example 1: Screening of sebum production inhibitors capable of enhancing the sebum production inhibitory effect by light irradiation 1. Cell culture and light irradiation treatment Human sebaceous gland cells (SK370, scalp-derived, CTI) were seeded on SebGln4 (CTI) and incubated with CO for 2 days. 2 Incubator (37 °C, 5% CO 2 After 2 days of culture, the collected human sebocytes were seeded at 9000 cells per well in a 24-well plate and cultured in SebGln4 medium. 2 Incubator (37 °C, 5% CO 2), the medium was then replaced with one containing a lipid synthesis inducer (Frozen Lipid Droplet Stimulator, CTI), and supplemented with 0.01% carnitine (Maruzen Pharmaceuticals Co., Ltd.), 1 μM diosmin (Tokyo Chemical Industry Co., Ltd.), 1 μM honokiol (Tokyo Chemical Industry Co., Ltd.), 0.1% lemon extract (Koei Kogyo Co., Ltd.), 0.1% raspberry extract (Iwaki Co., Ltd.), 0.1% hydrolyzed pearl protein extract (Iwaki Co., Ltd.), 0.1% witch hazel (Shiono Koryo Co., Ltd.), 0.1% camellia flower extract BG50 (Bioland Ltd.), and 0.1% camellia leaf extract BG50 (Bioland To the wells containing the vehicle, only the solvent for each drug or extract was added. The next day, the medium was replaced with warm HBSS(+) (Fujifilm Wako Pure Chemical Industries, Ltd.) and the cells were exposed to visible light for 15 minutes. A solar simulator was used for the irradiation, and GG420 and KG1 filters (Edmund Optics Japan, Inc.) were used to cut UV and IR. The intensity of the visible light was 36.2 mJ / cm. 2 The experiment was conducted under the same conditions in complete darkness for the non-exposed control group. After the light irradiation, the medium was replaced with SebGln4, and the cells were cultured for another 3 days, and after 3 days, the cells were irradiated with visible light in the same manner. The cells were cultured for another 2 days, and the number of cells and the amount of oil droplets were measured based on the method described below. The amount of sebum production was measured when each component of the non-exposed group was added relative to the amount of sebum production in the vehicle of the non-exposed control group, and this was taken as the sebum production inhibition rate. Similarly, in the light-exposed group, the amount of sebum production was measured when each component of the light-exposed group was added relative to the amount of sebum production in the non-exposed control, and this was taken as the sebum production inhibition rate. The results are shown in Figure 1 (white graph: non-exposed group, gray graph: light-exposed group). Furthermore, the amount of sebum production in the light-exposed group relative to that in the non-light-exposed group was calculated and shown as the rate of change (%) in sebum production due to light exposure (Figure 2).

[0042] 2. Cell Count The cultured cells were washed with warm PBS(-) (Nacalai Tesque), and a 5 μg / mL solution of Hoechst (registered trademark) 33342 (Thermo Fisher) / PBS was added, incubated for 30 minutes, washed again with warm PBS(-), and the fluorescence intensity (excitation wavelength 350 nm, fluorescence wavelength 461 nm) was measured using a BioTek multiplate reader. Hoechst (registered trademark) 33342 emits blue fluorescence when bound to double-stranded DNA, and was therefore used to measure the cell count.

[0043] 3. Measurement of Oil Droplet Production A lipid assay kit (PMC) was used to measure the amount of oil droplets. The cells for which the cell count was measured were immersed overnight in 10% neutral formalin (Fujifilm Wako Pure Chemical Industries, Ltd.) and fixed. After that, the cells were washed with ultrapure water and Oil Red O solution (PMC) was added. After incubating for 15 minutes, the cells were washed twice more with ultrapure water and the dye was extracted with an extract. The absorbance of the extract at 540 nm was measured and divided by the number of cells to obtain the amount of oil droplets per cell.

[0044] 4.Results When levocarnitine chloride, lemon extract, camellia flower extract, diosomine, fisetin, and honokiol were added, the amount of sebum production was decreased compared to the vehicle group. Therefore, these ingredients can be said to be sebum production inhibitors. Furthermore, components that further suppress sebum production when exposed to light include levocarnitine chloride, lemon extract, camellia flower extract, diosomin, fisetin, and honokiol, and these components can be called light-responsive sebum production inhibitors. In addition, raspberry extract, mangosteen extract, and camellia leaf extract did not have a sebum production inhibitory effect when not exposed to light, but did have a sebum production inhibitory effect when exposed to light. Therefore, these ingredients can be called light-responsive sebum production inhibitors, and in particular, they can be called biased light-responsive sebum production inhibitors.

Claims

1. A cosmetic method for enhancing the sebum production inhibitory effect, comprising applying to the skin a skin topical composition containing at least one light-responsive sebum production inhibitor selected from the group consisting of carnitine or a salt thereof, camellia flower extract, lemon extract, mangosteen extract, diosmin, raspberry extract, honokiol, camellia leaf extract, and fisetin, and placing the skin after application in the presence of light.

2. The cosmetic method according to claim 1, wherein the sebum production inhibitory effect of the photoresponsive sebum production inhibitor is enhanced in the presence of light.

3. The cosmetic method according to claim 1 or 2, for preventing stickiness, greasiness, and makeup from coming off.

4. A sebum production inhibitor comprising at least one component selected from the group consisting of carnitine or a salt thereof, lemon extract, camellia flower extract, fisetin, honokiol, and diosmin.

5. The sebum production inhibitor according to claim 4, wherein the sebum production inhibitory effect is enhanced in the presence of light.

6. The sebum production inhibitor according to claim 4 , which is contained in a light-shielding container.

7. A cosmetic composition for external application to the skin, comprising the sebum production inhibitor according to any one of claims 4 to 6, for preventing stickiness, greasiness, or makeup from coming off.

8. The composition for external application to skin according to claim 7 , further comprising a wavelength conversion substance that converts ultraviolet light into visible light.

9. A composition for external application to the skin for preventing, treating, or alleviating diseases caused by excessive sebum production, comprising the sebum production inhibitor according to any one of claims 4 to 6.

10. The composition for external use on the skin according to claim 9, further comprising a wavelength conversion substance that converts ultraviolet light into visible light.

11. The present invention relates to a method for producing a composition for external application to the skin for suppressing sebum production, and more particularly to a composition for external application to the skin for suppressing sebum production. The present invention relates to a composition for external application to the skin for suppressing sebum production. The present invention relates to a composition for external application to the skin for suppressing sebum production.

12. An apparatus for enhancing the sebum production inhibitory effect of a photoresponsive sebum production inhibitor, comprising an irradiation unit that irradiates light having a wavelength of 370 to 780 nm onto skin to which the photoresponsive sebum production inhibitor has been applied.

13. A beauty kit for enhancing a sebum production inhibitory effect, a composition for external use on the skin, comprising at least one photoresponsive sebum production inhibitor selected from the group consisting of carnitine or a salt thereof, camellia flower extract, lemon extract, mangosteen extract, diosmin, raspberry extract, honokiol, camellia leaf extract, and fisetin; The beauty kit further comprises an irradiation unit that irradiates light having a wavelength of 370 to 780 nm onto the skin to which the photoresponsive sebum production inhibitor has been applied, and a device for enhancing the sebum production inhibitory effect of the photoresponsive sebum production inhibitor.

Citation Information

Patent Citations

  • Sebum production inhibitor

    JP2011140460A

  • Sebum production inhibitor

    JP2013028572A

  • Lipid production-inhibiting agent, sebum production-inhibiting agent, and triacylglycerol production-inhibiting agent

    JP2013032331A

  • Sebum production inhibitor

    JP2021181494A